SCHEMBL5482116

SCHEMBL5482116

[CH2]N(C(C)=O)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
DGAT1 O75907 1/20 0.33
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20916878 0.87 HDAC6 (0.38) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL7856537 0.76 HDAC6 (0.33) HDAC6HDAC1HDAC2DGAT1
SCHEMBL206709 0.75 HDAC6 (0.37) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL7024160 0.75 HDAC6 (0.41) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL10558566 0.74 NFKB1 (0.44) HDAC6HDAC1HDAC2CA14
SCHEMBL8098483 0.73 HDAC6 (0.40) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL24700452 0.71 HDAC6 (0.39) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL15112990 0.71 HDAC6 (0.39) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL1462387 0.70 HDAC6 (0.38) HDAC6HDAC1HDAC2DGAT1CA14
SCHEMBL5345858 0.70 HDAC6 (0.34) HDAC6HDAC1HDAC2DGAT1CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015439-B1 PRENYL TRANSFERASE INHIBITORS SOD CONSEILS RECH APPLIC (FR) 2007-04-11 EP disclosed
EP-1676855-A2 Prenyl transferase inhibitors SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) 2006-07-05 EP disclosed
US-6313109-B2 ANTIPROLIFERATIVE AGENTS; TREATING TUMORS, RESTENOSIS SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES, SAS (FR) 2001-11-06 US disclosed
US-20010000344-A1 Prenyl transferase inhibitors BIOMEASURE INCORPORATED 2001-04-19 US disclosed
EP-1087981-A2 PRENYL TRANSFERASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2001-04-04 EP disclosed
US-6180619-B1 TREATING TUMORS OR RESTENOSIS BIOMEASURE, INCORPORATED 2001-01-30 US disclosed
WO-1999065922-A2 PRENYL TRANSFERASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 1999-12-23 WO disclosed
US-5767274-A TREATING TUMORS OR RESTENOSIS BIOMEASURE, INCORPORATED (US) 1998-06-16 US disclosed
EP-0017536-B1 PROCESS FOR THE PREPARATION OF SOMATOSTATINE SANOFI S.A. (FR) 1983-03-23 EP disclosed
EP-0017536-A2 Process for the preparation of somatostatine SANOFI S.A. (FR) 1980-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010000344-A1 Prenyl transferase inhibitors FNTA, FNTB, RCE1 HDAC6 1610/4885HDAC1 1189/4885HDAC2 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.